Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Merck Loses Around $32B in 3 Months: Time to Sell the Stock?

by Kinjel Shah

Declining estimates and the recent price drop make investors skeptical about holding MRK stock.

Zacks Equity Research

Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates

by Zacks Equity Research

Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.

Zacks Equity Research

Moderna (MRNA) Rises Higher Than Market: Key Facts

by Zacks Equity Research

The latest trading day saw Moderna (MRNA) settling at $69.17, representing a +1.3% change from its previous close.

Andrew Rocco headshot

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

by Andrew Rocco

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

by Zacks Equity Research

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Zacks Equity Research

Company News for Sep 13, 2024

by Zacks Equity Research

Companies in The News Are: KR,SIG,ALK,MRNA

Kinjel Shah headshot

Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?

by Kinjel Shah

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Zacks Equity Research

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

by Zacks Equity Research

The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.

Zacks Equity Research

Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

Zacks Equity Research

GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years

by Zacks Equity Research

The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.